Company Overview and News

 
ADMA / ADMA Biologics Inc null (Annual Report)

2018-03-29 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Upvote Downvote

 
ADMA Biologics: Almost Ready To Run Between The Toes Of Giants

2018-03-06 seekingalpha
ADMA’s lead product candidate has generated very positive clinical data, and is positioned to meet a very high unmet medical need.
Upvote Downvote

 
ADMA / ADMA Biologics Inc null (Current Report)

2018-03-05 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Upvote Downvote

 
ADMA / ADMA Biologics Inc null (Current Report)

2018-03-05 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Upvote Downvote

 
ADMA / ADMA Biologics Inc (Current Report)

2018-02-17 sec.gov
  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): February 15, 2018   ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter)       Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.
Upvote Downvote

 
ADMA / ADMA Biologics Inc (Current Report)

2018-02-15 sec.gov
  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): February 9, 2018   ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter)       Delaware 001-36728 56-2590442 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.
Upvote Downvote

 
ADMA / ADMA Biologics Inc / Consonance Capital Management LP - CONSONANCE CAPITAL MANAGEMENT LP (Passive Investment)

2018-02-14 sec.gov
admaa3_21418.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* ADMA Biologics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 000899 104 (CUSIP Number) December 31, 2017 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [   ] Rule 13d-1(c
Upvote Downvote

 
ADMA / ADMA Biologics Inc / Consonance Capital Management LP - CONSONANCE CAPITAL MANAGEMENT LP (Passive Investment)

2018-02-14 sec.gov
admaa3_21418.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* ADMA Biologics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 000899 104 (CUSIP Number) December 31, 2017 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [   ] Rule 13d-1(c
Upvote Downvote

 
ADMA / ADMA Biologics Inc / Broadfin Capital, LLC - 3G/A (Passive Investment)

2018-02-13 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549   SCHEDULE 13G   Under the Securities Exchange Act of 1934 (Amendment No. 2)*     ADMA Biologics, Inc. (Name of Issuer)     Common Stock, par value $0.0001 per share (Title of Class of Securities)     000899104 (CUSIP Number)     December 31, 2017 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [_] Rule 13d-1(b)   [X] Rule 13d
Upvote Downvote

 
ADMA / ADMA Biologics Inc / Broadfin Capital, LLC - 3G/A (Passive Investment)

2018-02-13 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549   SCHEDULE 13G   Under the Securities Exchange Act of 1934 (Amendment No. 2)*     ADMA Biologics, Inc. (Name of Issuer)     Common Stock, par value $0.0001 per share (Title of Class of Securities)     000899104 (CUSIP Number)     December 31, 2017 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [_] Rule 13d-1(b)   [X] Rule 13d
Upvote Downvote

 
ADMA / ADMA Biologics Inc ER

2018-01-01 sec.gov
October 18, 2017 Adam S. Grossman President and Chief Executive Officer ADMA Biologics, Inc. 465 State Route 17 Ramsey, New Jersey 07446 Re: ADMA Biologics, Inc. Registration Statement on Form S-1 Filed October 11, 2017 File No. 333-220910 Dear Mr. Grossman: We have limited our review of your registration statement to those issues we have addressed in our comment. Please respond to this letter by amending your registration statement and providing the requested informat
Upvote Downvote

 
ADMA / ADMA Biologics Inc ESP

2018-01-01 sec.gov
    DLA Piper LLP (US) 51 John F. Kennedy Parkway, Suite 120 Short Hills, New Jersey 07078-2704 www.dlapiper.com   David C. Schwartz david.schwartz@dlapiper.com T  973.520.2555 F  973.520.2575   Partners Responsible for Short Hills Office: Andrew P. Gilbert Michael E. Helmer     October 23, 2017       Via UPS Overnight     Office of the Secretary Room 10915 Mail Stop 1090 Securities and Exchange Commission 100 F Street, NE Washington, DC 20549-1090     Re: ADMA Biologics, Inc.
Upvote Downvote

 
ADMA / ADMA Biologics Inc ESP

2018-01-01 sec.gov
   RAYMOND JAMES & ASSOCIATES, INC. 880 Carillon Parkway St. Petersburg, Florida 33716   November 6, 2017   VIA EDGAR   U.S. Securities and Exchange Commission 100 F St., NE Washington D.C. 20549   Attention:   Irene J. Paik, Attorney Adviser       Re:   ADMA Biologics, Inc.     Registration Statement on Form S-1 (File No. 333-220910)   Ladies and Gentlemen:   Pursuant to Rule 461 of the General Rules and Regulations of the U.
Upvote Downvote

 
ADMA / ADMA Biologics Inc ESP

2018-01-01 sec.gov
  ADMA Biologics, Inc. 465 State Route 17 Ramsey, New Jersey 07446   November 6, 2017   Via EDGAR   Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549-4561   Attn:   Irene J. Paik, Attorney Adviser                       Re: ADMA Biologics, Inc. (the “Company”)         Registration Statement on Form S-1         Filed October 11, 2017, as amended         File No.
Upvote Downvote

2
Weekly Insider Trading

2017-12-28 seekingalpha
It is Christmas time and some extra time to... work! My pilot article ("Weekly Insider Trading") was published as recently as December 23, but it covered four biotech and IT companies with the most interesting insider trading dating back 3 months. This article follows my standard work and investing process by looking back at the last week’s most interesting transactions.
Upvote Downvote

Related Articles

LPCN: Lipocine Inc Analysis and Research Report

2h - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

CUSIP: 000899104